University of Miami Miller School Plays Pivotal Role in Securing a $15 Million National Alzheimer’s Disease Research Center

University of Miami Miller School of Medicine investigators play a pivotal role in a consortium of Florida institutions just awarded a $15 million grant to collaborate on Alzheimer’s disease research. The five-year National Institutes of Health/National Institute on Aging grant brings together top Florida researchers to focus on better understanding how to diagnose, treat, prevent, and potentially cure Alzheimer’s in diverse populations.

Read more

Blood Vessel Defects in Eyes May Foretell Alzheimer’s

Alzheimer’s disease in its early stages affects the integrity of small blood vessels in the retinas of patients, according to a recent study led by Cedars-Sinai. This discovery holds promise for early diagnosis of Alzheimer’s through the retina, a back-of-the-eye organ that is an extension of the brain and easily accessible for live, noninvasive imaging.

Read more

Embargoed: Forthcoming Report To Examine Alzheimer’s and Other Dementias in U.S.

The Alzheimer’s Association will issue the 2020 Alzheimer’s Diseases Facts and Figures Report on March 11, 2020. The new report will highlight the latest disease-related statistics for America’s 6th leading cause of death for those 65+, including prevalence, incidence, mortality, costs of care and impact on caregivers both nationally, as well as state by state data, for both 2020 and future projections. This new report will feature findings from a first-of-its-kind, comprehensive survey of primary care physicians (PCPs) and medical school residents which examines the medical profession’s readiness to meet future care needs for the growing number of people living with Alzheimer’s and other dementias. Information and report findings are under strict embargo until Wednesday, March 11, 2020.

Read more

IU School of Medicine awarded $36 million NIH grant for Alzheimer’s disease drug discovery center

The IU-led center is one of only two multi-institution teams in the nation selected as part of a new federal program intended to improve, diversify and reinvigorate the Alzheimer’s disease drug development pipeline.

Read more